INTRODUCTION
In neurological diseases such as Parkinson's disease (PD), spontaneous regeneration is not sufficient to repair degenerated neuronal systems (Guttman et al., 1997) . Research has therefore focused on finding specific factors that can protect and stimulate the regenerative abilities of neural systems. In animal models of PD, neurotrophic effects on the selectively vulnerable dopamine (DA) neurons have been obtained with various factors, including brain-derived neurotrophic factor (Altar et al., 1994; Frim et al., 1994; Galpern et al., 1996) , glial-derived neurotrophic factor (Hoffer et al., 1994; Kearns & Gash, 1995; Sauer et al., 1995; Tomac et al., 1995; Hou et al., 1996) , transforming growth factor-␤ (Krieglstein & Unsicker, 1994; Kreiglstein et al., 1995a,b) , and basic fibroblast growth factor (Date et al., 1993) . Nonetheless, clinical application has been limited by administration methods and bioavailability of these peptide factors.
Trophic activity has also been observed with the immunosuppressant drug FK506 in a variety of in vitro and in vivo models: FK506 increases the ability of nerve growth factor (NGF) to stimulate neurite outgrowth in the PC12 cell line and dorsal root ganglion explants (Lyons et al., 1994; Steiner et al., 1997a) and stimulates nerve regrowth after sciatic nerve injury (Gold et al., 1995) . The immunosuppressive effects of FK506 render the drug unsuitable for chronic administration to neurodegenerative disease patients. Both the neurotrophic and the immunosuppressive effects of FK506 are thought to be mediated by its specific cellular
